Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Paul F. Lizzul is Chief Medical Officer at First Tracks Biotherapeutics. OQRO lists 1 transaction filed with the SEC under this name, the latest on Nov 3, 2026, each linked to the official Form 4.
Chief Medical Officer
Disclosures on record
1
Companies involved
1
First Tracks BiotherapeuticsTRAX
Nov 1, 202643Kdisclosed Nov 3
DetailsOfficial recordPaul F. Lizzul has no open-market purchase on record since 2023. Sales in 2 of the 4 years since 2023.
Paul F. Lizzul reported 0 open-market purchases and 6 sales since 2023; no open-market purchase.
| Year | Bought | Sold |
|---|---|---|
| 2024 | — | $333K5×5 trades |
| 2023 | — | $41K1×1 trade |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Paul F. Lizzul reported 0 open-market purchases and 6 sales here, 2023 to 2024.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.
Paul F. Lizzul has no open-market purchase on record since 2023. Sales in 2 of the 4 years since 2023.
In SEC filings since 2023: no open-market purchase is on record; the latest open-market sale is from 2024.
Anaptysbio (ANAB), from 2023 to 2024: 0 purchases and 6 sales.